| Chapter title |
Cancer Nanotherapeutics in Clinical Trials
|
|---|---|
| Chapter number | 13 |
| Book title |
Nanotechnology-Based Precision Tools for the Detection and Treatment of Cancer
|
| Published in |
Cancer treatment and research, April 2015
|
| DOI | 10.1007/978-3-319-16555-4_13 |
| Pubmed ID | |
| Book ISBNs |
978-3-31-916554-7, 978-3-31-916555-4
|
| Authors |
Abigail K. R. Lytton-Jean, Kevin J. Kauffman, James C. Kaczmarek, Robert Langer, Lytton-Jean, Abigail K R, Kauffman, Kevin J, Kaczmarek, James C, Langer, Robert, Lytton-Jean, Abigail K. R., Kauffman, Kevin J., Kaczmarek, James C. |
| Abstract |
To be legally sold in the United States, all drugs must go through the FDA approval process. This chapter introduces the FDA approval process and describes the clinical trials required for a drug to gain approval. We then look at the different cancer nanotherapeutics and in vivo diagnostics that are currently in clinical trials or have already received approval. These nanotechnologies are catagorized and described based on the delivery vehicle: liposomes, polymer micelles, albumin-bound chemotherapeutics, polymer-bound chemotherapeutics, and inorganic particles. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Practitioners (doctors, other healthcare professionals) | 1 | 50% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 4% |
| Unknown | 23 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 4 | 17% |
| Student > Ph. D. Student | 4 | 17% |
| Student > Bachelor | 3 | 13% |
| Lecturer | 2 | 8% |
| Librarian | 1 | 4% |
| Other | 4 | 17% |
| Unknown | 6 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 4 | 17% |
| Agricultural and Biological Sciences | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Business, Management and Accounting | 1 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 1 | 4% |
| Other | 7 | 29% |
| Unknown | 8 | 33% |